India, Dec. 20 -- President Donald Trump on Friday unveiled new agreements with nine major pharmaceutical companies aimed at lowering the prices Americans pay for certain prescription drugs, part of a broader push to bring US costs closer to those in Europe.

"We were subsidizing the entire world. We're not doing it anymore," Trump said at a White House press conference.

The latest deals involve Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech (Roche), Gilead, GSK, Merck, Novartis and Sanofi.

With these agreements, the administration has now secured commitments from 14 of the 17 drugmakers it formally pressed in July to cut prices. In recent months, similar arrangements were announced with Pfizer, AstraZeneca, EMD Serono, El...